BiomX Inc.
(NYSE: PHGE)
Rigrodsky Law, P.A. is investigating BiomX Inc. (“BiomX”) regarding possible breaches of fiduciary duties and other violations of law related to BiomX’s agreement to be acquired by Adaptive Phage Therapeutics. Under the terms of the agreement, BiomX will issue 9,164,967 shares of BiomX common stock, 40,471 shares of Series X Preferred Stock convertible into 40,471,000 shares of BiomX common stock and warrants exercisable for 2,166,497 shares of BiomX common stock.